294 results on '"Berman, Robert M."'
Search Results
2. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
3. Augmentation treatment in major depressive disorder: focus on aripiprazole
4. Prophylactic efficacy of riluzole against anxiety- and depressive-like behaviors in two rodent stress models
5. Comparison of “Word” vs. “Picture” version of the Free and Cued Selective Reminding Test (FCSRT) in older adults
6. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: A pooled analysis
7. Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers
8. Octapeptides Deduced from the Neuropeptide Receptor-Like Pattern of Antigen T4 in Brain Potently Inhibit Human Immunodeficiency Virus Receptor Binding and T-Cell Infectivity
9. Morphological, Biochemical, and Molecular Changes in Endothelial Cells after Alpha-Particle Irradiation
10. Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men
11. A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects
12. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy
13. Subjective evaluation of the therapeutic and cognitive effects of electroconvulsive therapy
14. Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models
15. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat
16. Principles of the Pharmacotherapy of Depression
17. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression
18. Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
19. Cerebrovascular reactivity following administration of mirtazapine in healthy probands – A randomized, placebo controlled double-blind clinical study
20. Prophylactic efficacy of riluzole against anxiety- and depressive-like behaviors in two rodent stress models
21. Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym
22. A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV‐0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers
23. Bulimia nervosa and alcohol dependence: a case report of a patient enrolled in a randomized controlled clinical trial
24. Cognitive function over the treatment course of depression in middle-aged patients: correlation with brain MRI signal hyperintensities
25. Open-Label Flexible-Dose Pilot Study to Evaluate the Safety and Tolerability of Aripiprazole in Patients With Psychosis Associated With Parkinsonʼs Disease
26. Regional Brain Metabolic Correlates of α-Methylparatyrosine–Induced Depressive Symptoms: Implications for the Neural Circuitry of Depression
27. Increased Cortical GABA Concentrations in Depressed Patients Receiving ECT
28. Transcranial magnetic stimulation and auditory hallucinations in schizophrenia
29. Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists
30. Reduced Cortical γ-Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy
31. Transient Depressive Relapse Induced by Catecholamine Depletion: Potential Phenotypic Vulnerability Marker?
32. A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers (S5.005)
33. Results from the Long-Term Open Label Extension Phase Analyses of BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia (P1.8-001)
34. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression
35. Drs. Berman and Charney Reply
36. Effect of Pindolol in Hastening Response to Fluoxetine in the Treatment of Major Depression: A Double-Blind, Placebo-Controlled Trial
37. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression
38. A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV‐0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers.
39. Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder
40. Symptom provocation studies in psychiatric disorders: scientific value, risks, and future
41. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial
42. Reduced Cortical [gama]-Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy
43. Improving Alzheimer’s disease phase II clinical trials
44. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat
45. Did plate tectonics shutdown in the Palaeoproterozoic? A view from the Siderian geologic record
46. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study
47. IC-P-108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION
48. P2-202: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION
49. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy
50. Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.